Watch President Obama's Address on the Supreme Court's Decision

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.

Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

The FDA cleared PrecivityAD2, a blood test from C2N Diagnostics that helps diagnose Alzheimer disease in adults as young as 40.